CD8A and neoplasm: Previously, CD8 T cells generated by vaccination with full-length Mam-A DNA were able to specifically induce the regression of Mam-A+ breast cancer tumors in vivo[3], [4] but their ability to provide long-term tumor specific immunity was not determined.